|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
|
WO2002014495A2
(en)
*
|
2000-08-14 |
2002-02-21 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced homologous recombination mediated by lambda recombination proteins
|
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
CA2487058C
(en)
|
2002-05-17 |
2015-04-14 |
Mount Sinai School Of Medicine Of New York University |
Mesoderm and definitive endoderm cell populations
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
PT2314629E
(pt)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Produção recombinante de misturas de anticorpos
|
|
AU2003278790A1
(en)
*
|
2002-09-09 |
2004-03-29 |
California Institute Of Technology |
Methods and compositions for the generation of humanized mice
|
|
WO2004067725A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of identifying modulators of nmur2-mediated activity
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP2395016A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
AU2005295269B2
(en)
|
2004-10-19 |
2010-05-13 |
Regeneron Pharmaceuticals, Inc. |
Method for generating an animal homozygous for a genetic modification
|
|
US20060117396A1
(en)
*
|
2004-11-30 |
2006-06-01 |
Murphy Andrew J |
Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
|
|
US20090263900A1
(en)
*
|
2008-04-14 |
2009-10-22 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
EP2125894B1
(en)
|
2007-03-22 |
2018-12-19 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
|
KR102096731B1
(ko)
|
2007-06-01 |
2020-04-02 |
오픈 모노클로날 테크놀로지, 인코포레이티드 |
내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
|
|
KR20100103810A
(ko)
*
|
2007-12-10 |
2010-09-28 |
알리바 바이오파마수티컬스, 아이엔씨. |
동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
|
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
|
DE102008002715A1
(de)
*
|
2008-06-27 |
2009-12-31 |
Evonik Röhm Gmbh |
2-Hydroxyisobuttersäure produzierende rekombinante Zelle
|
|
KR101987351B1
(ko)
|
2008-09-30 |
2019-06-10 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 인간 이외의 포유동물
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CN102638971B
(zh)
|
2009-07-08 |
2015-10-07 |
科马布有限公司 |
动物模型及治疗分子
|
|
CA3040377C
(en)
|
2009-10-06 |
2025-12-30 |
Yale University |
Genetically modified mice and engraftment comprising the knock-in of a human thrombopoietin (tpo) gene
|
|
WO2011059799A1
(en)
|
2009-10-29 |
2011-05-19 |
Regeneron Pharmaceuticals, Inc. |
Multifunctional alleles
|
|
WO2011072204A1
(en)
|
2009-12-10 |
2011-06-16 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
MY156743A
(en)
|
2009-12-21 |
2016-03-31 |
Regeneron Pharma |
Humanized fc?r mice
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US10143186B2
(en)
|
2010-02-08 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
KR101830020B1
(ko)
|
2010-03-31 |
2018-02-19 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
SG10201504568YA
(en)
|
2010-06-22 |
2015-07-30 |
Regeneron Pharma |
Hybrid light chain mice
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
DK2597945T3
(da)
|
2010-07-26 |
2020-09-21 |
Trianni Inc |
Transgene dyr og fremgangsmåder til anvendelse deraf
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
EP3960865A1
(en)
|
2010-08-02 |
2022-03-02 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
WO2012063048A1
(en)
|
2010-11-08 |
2012-05-18 |
Kymab Limited |
Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
ES3040596T3
(en)
|
2011-02-15 |
2025-11-03 |
Regeneron Pharma |
Humanized m-csf mice and uses thereof
|
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
|
ME03732B
(me)
|
2011-02-25 |
2021-01-20 |
Regeneron Pharma |
Miševi s ADAM6
|
|
ES2541535T3
(es)
|
2011-05-12 |
2015-07-21 |
Regeneron Pharmaceuticals, Inc. |
Ensayo de liberación de neuropéptido para canales de sodio
|
|
HRP20192255T1
(hr)
|
2011-08-05 |
2020-03-06 |
Regeneron Pharmaceuticals, Inc. |
Humanizirani miševi s univerzalnim lakim lancem
|
|
BR112014006390A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
|
|
JP2014531452A
(ja)
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
HRP20220253T1
(hr)
|
2011-10-17 |
2022-04-29 |
Regeneron Pharmaceuticals, Inc. |
Miševi s ograničenim teškim lancem imunoglobulina
|
|
RS56656B1
(sr)
|
2011-10-28 |
2018-03-30 |
Regeneron Pharma |
Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
CN114891797A
(zh)
|
2011-10-28 |
2022-08-12 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
RS56330B1
(sr)
|
2011-10-28 |
2017-12-29 |
Regeneron Pharma |
Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
|
|
AU2012332894A1
(en)
|
2011-10-31 |
2014-05-08 |
Merck Sharp & Dohme Corp. |
Nano-suspension process
|
|
GB201122047D0
(en)
*
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
ME03477B
(me)
|
2011-12-20 |
2020-01-20 |
Regeneron Pharma |
Miševi sa humanizovanim lakim lancem
|
|
SG10201913428QA
(en)
|
2012-02-01 |
2020-03-30 |
Regeneron Pharma |
Humanized rodents that express heavy chains containing vl domains
|
|
CA2865029A1
(en)
|
2012-03-06 |
2013-09-12 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
RU2014141536A
(ru)
|
2012-03-16 |
2016-05-10 |
Регенерон Фармасьютикалз, Инк. |
Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
|
|
PT2825037T
(pt)
|
2012-03-16 |
2019-08-07 |
Regeneron Pharma |
Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
|
|
SMT201800395T1
(it)
|
2012-03-16 |
2018-09-13 |
Regeneron Pharma |
Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
|
|
EP2831245A1
(en)
|
2012-03-28 |
2015-02-04 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
|
KR102484480B1
(ko)
|
2012-06-12 |
2023-01-04 |
리제너론 파마슈티칼스 인코포레이티드 |
제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
|
|
AR091482A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Recombinetics Inc |
Celulas modificadas geneticamente y metodos par su obtencion
|
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
KR102287541B1
(ko)
|
2012-09-07 |
2021-08-10 |
예일 유니버시티 |
유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
|
|
UA118090C2
(uk)
*
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
EP4389764B1
(en)
|
2012-11-05 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified rodents and methods of use thereof
|
|
KR20240147707A
(ko)
|
2013-02-20 |
2024-10-08 |
리제너론 파아마슈티컬스, 인크. |
사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
|
|
LT2840892T
(lt)
*
|
2013-02-20 |
2018-07-25 |
Regeneron Pharmaceuticals, Inc. |
Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
|
|
AU2014218931C1
(en)
|
2013-02-20 |
2020-05-14 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
CN110192541B
(zh)
|
2013-02-22 |
2022-02-18 |
瑞泽恩制药公司 |
表达人源化主要组织相容性复合物的小鼠
|
|
CA2902543A1
(en)
|
2013-03-11 |
2014-10-09 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
|
|
EP4249507A3
(en)
|
2013-03-11 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
LT3501272T
(lt)
|
2013-03-13 |
2023-03-27 |
Regeneron Pharmaceuticals, Inc. |
Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
|
|
SG11201506294TA
(en)
|
2013-03-13 |
2015-09-29 |
Regeneron Pharma |
Common light chain mouse
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA2908697C
(en)
|
2013-04-16 |
2023-12-12 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
|
CN105518132B
(zh)
|
2013-08-07 |
2021-02-05 |
瑞泽恩制药公司 |
缺乏lincRNA的非人类动物
|
|
KR20200103882A
(ko)
|
2013-09-18 |
2020-09-02 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
|
|
DK3175706T3
(en)
|
2013-09-23 |
2019-03-04 |
Regeneron Pharma |
Non-human animals with a humanized signal regulatory protein gene
|
|
ES2993142T3
(en)
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
SG10201811701YA
(en)
|
2013-11-19 |
2019-01-30 |
Regeneron Pharma |
Non-human animals having a humanized a proliferation-inducing ligand gene
|
|
CN105792646B
(zh)
|
2013-11-19 |
2018-03-02 |
瑞泽恩制药公司 |
具有人源化的b细胞活化因子基因的非人动物
|
|
SG10201700961TA
(en)
*
|
2013-12-11 |
2017-04-27 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
|
HUE041331T2
(hu)
|
2013-12-11 |
2019-05-28 |
Regeneron Pharma |
Módszerek és készítmények a genom célzott módosításához
|
|
WO2015108102A1
(ja)
|
2014-01-15 |
2015-07-23 |
国立大学法人 群馬大学 |
Ａｔｐ可視化動物およびその用途
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
BR112016021679A2
(pt)
|
2014-03-21 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
|
|
SG10201808225TA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Non-human animals that make single domain binding proteins
|
|
KR20250096864A
(ko)
|
2014-05-19 |
2025-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
인간 epo를 발현하는 유전자 변형된 비-인간 동물
|
|
ES2877275T3
(es)
|
2014-05-30 |
2021-11-16 |
Regeneron Pharma |
Animales con dipeptidil peptidasa IV (DPP4) humanizada
|
|
HUE049776T2
(hu)
|
2014-06-06 |
2020-10-28 |
Regeneron Pharma |
Módszerek és készítmények egy célzott lókusz módosítására
|
|
HUE048677T2
(hu)
|
2014-06-19 |
2020-07-28 |
Regeneron Pharma |
Humanizált programozott sejthalál 1 génnel rendelkezõ nem-humán állatok
|
|
MX384887B
(es)
|
2014-06-23 |
2025-03-14 |
Regeneron Pharma |
Ensamblaje de adn mediado por nucleasa.
|
|
EP3161128B1
(en)
|
2014-06-26 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
WO2016044745A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
|
DK3207124T3
(da)
|
2014-10-15 |
2019-08-12 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
|
|
EP3221457B1
(en)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
KR20240055876A
(ko)
|
2014-11-24 |
2024-04-29 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 cd3 복합체를 발현하는 비인간 동물
|
|
KR102617691B1
(ko)
|
2014-12-05 |
2023-12-27 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 분화 클러스터 47 유전자를 가진 비인간 동물
|
|
NZ731954A
(en)
|
2014-12-09 |
2024-11-29 |
Regeneron Pharma |
Non-human animals having a humanized cluster of differentiation 274 gene
|
|
JP6840077B2
(ja)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
|
|
ES2884844T3
(es)
|
2015-03-09 |
2021-12-13 |
Agensys Inc |
Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
|
|
RU2744831C2
(ru)
|
2015-03-16 |
2021-03-16 |
Регенерон Фармасьютикалз, Инк. |
Не относящееся к человеку животное, у которого проявляется снижение функции верхних и нижних моторных нейронов и чувственного восприятия
|
|
HK1250038A1
(zh)
|
2015-03-19 |
2018-11-23 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
KR20240132525A
(ko)
|
2015-04-06 |
2024-09-03 |
리제너론 파아마슈티컬스, 인크. |
비인간 동물에서의 인간화 t 세포 매개 면역반응
|
|
JP6752221B2
(ja)
|
2015-04-13 |
2020-09-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
|
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
|
WO2016187354A1
(en)
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
JP6913030B2
(ja)
|
2015-05-18 |
2021-08-04 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
RU2725737C2
(ru)
*
|
2015-05-29 |
2020-07-03 |
Регенерон Фармасьютикалс, Инк. |
Животные, отличные от человека, с нарушением в локусе c9orf72
|
|
EP3344034A1
(en)
|
2015-09-02 |
2018-07-11 |
Regeneron Pharmaceuticals, Inc. |
Rodent model of prostate cancer
|
|
TW202417497A
(zh)
|
2015-10-12 |
2024-05-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
AU2016358101B2
(en)
*
|
2015-11-20 |
2022-12-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized Lymphocyte-activation gene 3
|
|
JP7098521B2
(ja)
*
|
2015-11-24 |
2022-07-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
レトロウイルス産生のための安定な細胞株
|
|
FR3044017B1
(fr)
*
|
2015-11-24 |
2019-05-03 |
Glaxosmithkline Intellectual Property Development Limited |
Procede de transfection transitoire pour la production retrovirale
|
|
EP3384030A4
(en)
|
2015-12-03 |
2019-07-03 |
Trianni, Inc. |
IMPROVED IMMUNOGLULINIVITY
|
|
EP3402326A1
(en)
|
2016-01-13 |
2018-11-21 |
Regeneron Pharmaceuticals, Inc. |
Rodents having an engineered heavy chain diversity region
|
|
US20170218398A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Markus Alexander Brown |
Method to selectively target cancerous cells for genetic manipulation
|
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
CN108779159B
(zh)
|
2016-02-04 |
2022-12-30 |
瑞泽恩制药公司 |
具有经改造的angptl8基因的非人动物
|
|
US12071669B2
(en)
|
2016-02-12 |
2024-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for detection of abnormal karyotypes
|
|
RU2018130010A
(ru)
|
2016-02-16 |
2020-03-17 |
Регенерон Фармасьютикалз, Инк. |
Животные, отличные от человека, имеющие мутантный ген кинурениназы
|
|
JP6980674B2
(ja)
|
2016-02-29 |
2021-12-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ヒト化ｔｍｐｒｓｓ遺伝子を有する齧歯類
|
|
SG11201808261RA
(en)
|
2016-03-29 |
2018-10-30 |
Regeneron Pharma |
Genetic variant-phenotype analysis system and methods of use
|
|
CN109475109B
(zh)
|
2016-05-20 |
2021-10-29 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
SI3462853T1
(sl)
|
2016-06-03 |
2023-05-31 |
Regeneron Pharmaceuticals, Inc. |
Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
|
|
MX2018016330A
(es)
|
2016-06-27 |
2020-02-17 |
Univ California |
Combinaciones para tratamiento del cáncer.
|
|
DK3476865T5
(da)
|
2016-06-28 |
2024-09-09 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
|
|
RU2721125C1
(ru)
|
2016-07-29 |
2020-05-18 |
Регенерон Фармасьютикалз, Инк. |
Мыши, содержащие мутации, вследствие которых экспрессируется укороченный на с-конце фибриллин-1
|
|
CA3038548A1
(en)
|
2016-09-30 |
2018-04-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus
|
|
EP3766343B1
(en)
|
2016-11-04 |
2022-05-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
|
SG10202109874VA
(en)
|
2017-01-19 |
2021-10-28 |
Open Monoclonal Tech Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
RU2019125818A
(ru)
|
2017-02-27 |
2021-03-29 |
Регенерон Фармасьютикалс, Инк. |
Модели ретиношизиса на животных, отличных от человека
|
|
EP3585160A2
(en)
|
2017-07-31 |
2020-01-01 |
Regeneron Pharmaceuticals, Inc. |
Crispr reporter non-human animals and uses thereof
|
|
SG11201912235PA
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharma |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof
|
|
CN116376973A
(zh)
|
2017-09-29 |
2023-07-04 |
瑞泽恩制药公司 |
经基因修饰的啮齿动物基因组
|
|
ES2962277T3
(es)
|
2017-09-29 |
2024-03-18 |
Regeneron Pharma |
Roedores que comprenden un locus Ttr humanizado y métodos de uso
|
|
WO2019072241A1
(en)
*
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
CN109666701B
(zh)
*
|
2017-10-13 |
2021-08-24 |
百奥赛图(北京)医药科技股份有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
IL274740B2
(en)
|
2017-11-30 |
2024-06-01 |
Regeneron Pharma |
Non-human animals comprising a humanized trkb locus
|
|
LT3720279T
(lt)
|
2017-12-05 |
2022-10-25 |
Regeneron Pharmaceuticals, Inc. |
Pelės, turinčios sukonstruotą imunoglobulino lambda lengvąją grandinę, ir jų panaudojimas
|
|
KR20240038811A
(ko)
|
2018-03-19 |
2024-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
|
|
JP7328243B2
(ja)
|
2018-03-26 |
2023-08-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療薬を試験するためのヒト化げっ歯類
|
|
PT3773713T
(pt)
|
2018-04-06 |
2025-07-29 |
Regeneron Pharma |
Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
|
|
EP3811364A1
(en)
|
2018-06-01 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
HRP20240999T1
(hr)
|
2018-07-16 |
2024-10-25 |
Regeneron Pharmaceuticals, Inc. |
Glodavački modeli bolesti ditra i njihova upotreba
|
|
CN109504708A
(zh)
*
|
2018-12-03 |
2019-03-22 |
江苏集萃药康生物科技有限公司 |
一种筛选标记自我删除的基因打靶载体及方法
|
|
US11690362B2
(en)
|
2018-12-20 |
2023-07-04 |
Regeneran Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
|
WO2020152607A1
(en)
|
2019-01-22 |
2020-07-30 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
|
WO2020169022A1
(en)
|
2019-02-18 |
2020-08-27 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
SG11202107589PA
(en)
|
2019-02-22 |
2021-08-30 |
Regeneron Pharma |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
WO2020206139A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
|
US11111504B2
(en)
|
2019-04-04 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
MX2021014893A
(es)
|
2019-06-05 |
2022-03-11 |
Regeneron Pharma |
Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
|
|
AU2020289581B2
(en)
|
2019-06-07 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
|
CA3139469A1
(en)
|
2019-06-27 |
2020-12-30 |
Aarti Sharma-Kanning |
Modeling tdp-43 proteinopathy
|
|
JP7775080B2
(ja)
|
2019-07-01 |
2025-11-25 |
トニックス ファーマ リミテッド |
抗ｃｄ１５４抗体およびその使用
|
|
US12202893B2
(en)
|
2019-10-04 |
2025-01-21 |
Tae Life Sciences, Llc |
Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
US12250931B2
(en)
|
2020-01-28 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mouse with a humanized PNPLA3 gene and methods of use
|
|
EP4099821A1
(en)
|
2020-02-07 |
2022-12-14 |
Regeneron Pharmaceuticals, Inc. |
<smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
|
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
JP7765403B2
(ja)
|
2020-04-21 |
2025-11-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
|
|
IL298632A
(en)
|
2020-06-02 |
2023-01-01 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Non-human animals genetically modified with a common light chain immunoglobulin locus
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
KR20230024822A
(ko)
|
2020-06-25 |
2023-02-21 |
주식회사 휴맵 |
이형접합성 형질전환 동물
|
|
EP4211155A1
(en)
|
2020-09-11 |
2023-07-19 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
|
US12082566B2
(en)
|
2020-10-01 |
2024-09-10 |
Regeneron Pharmaceuticals, Inc. |
Rodent animals expressing human CR1
|
|
US12012441B2
(en)
|
2020-10-26 |
2024-06-18 |
Neptune Biosciences Llc |
Engineered human IL-21 cytokines and methods for using the same
|
|
CA3199879A1
(en)
|
2020-12-16 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
JP2024500153A
(ja)
|
2020-12-21 |
2024-01-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｔｓｌｐ遺伝子、ヒト化ｔｓｌｐ受容体遺伝子、及び／又はヒト化ｉｌ７ｒａ遺伝子を有する非ヒト動物
|
|
US20240317849A1
(en)
|
2020-12-23 |
2024-09-26 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
US20240059781A1
(en)
|
2021-01-06 |
2024-02-22 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
|
AU2022249328A1
(en)
|
2021-03-31 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
|
|
WO2022220603A1
(ko)
|
2021-04-16 |
2022-10-20 |
고려대학교 산학협력단 |
코로나-19 바이러스 표적 인간 항체
|
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
US20250049006A1
(en)
|
2021-12-20 |
2025-02-13 |
C/O Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
US20250194571A1
(en)
|
2022-02-07 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
JP2025506095A
(ja)
|
2022-02-11 |
2025-03-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
４ｒタウ標的化剤をスクリーニングするための組成物及び方法
|
|
WO2023212560A1
(en)
|
2022-04-26 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
|
WO2024020057A1
(en)
|
2022-07-19 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified animal model and its use to model the human immune system
|
|
KR20250077529A
(ko)
|
2022-09-22 |
2025-05-30 |
리제너론 파아마슈티컬스, 인크. |
인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
|
|
WO2024073679A1
(en)
|
2022-09-29 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
EP4658066A1
(en)
|
2023-02-01 |
2025-12-10 |
Regeneron Pharmaceuticals, Inc. |
Animals comprising a modified klhdc7b locus
|
|
AU2024304180A1
(en)
|
2023-06-13 |
2026-01-08 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
CN121335619A
(zh)
|
2023-06-16 |
2026-01-13 |
瑞泽恩制药公司 |
载体、经基因修饰的细胞和包含其的经基因修饰的非人动物
|
|
WO2025122669A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized complement factor b gene
|
|
WO2025171307A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025212991A1
(en)
|
2024-04-05 |
2025-10-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent models of disease
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|
|
WO2025264533A1
(en)
|
2024-06-17 |
2025-12-26 |
Adcentrx Therapeutics Inc. |
Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
WO2026035843A2
(en)
|
2024-08-06 |
2026-02-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026039661A1
(en)
|
2024-08-15 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with humanized fc epsilon receptors that lack functional alpha-1, 3-galactosyltransferase (ggta1)
|